Very very good announcement
Organic revenue for Q4 is around $7.4M before BHA, which we know they generally are conservative with forecasts.
I was anticipating $7.2M but I'll upgrade that to $8.0M
Even more impressive is the low churn numbers
Churn was going to be one of the biggest risks for future revenue for the company. It looks like they have this under control at the moment
Very happy
- Forums
- ASX - By Stock
- BIG
- Ann: FY17 Cash Revenue Guidance Update
Ann: FY17 Cash Revenue Guidance Update, page-2
-
- There are more pages in this discussion • 84 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BIG (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online